US20020197291A1 - Composition for removing abnormal keratinous material - Google Patents
Composition for removing abnormal keratinous material Download PDFInfo
- Publication number
- US20020197291A1 US20020197291A1 US10/156,070 US15607002A US2002197291A1 US 20020197291 A1 US20020197291 A1 US 20020197291A1 US 15607002 A US15607002 A US 15607002A US 2002197291 A1 US2002197291 A1 US 2002197291A1
- Authority
- US
- United States
- Prior art keywords
- weight
- percent
- preparation
- amount
- urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8176—Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
Definitions
- the present invention relates to a preparation comprising urea, a hydrophilic film-forming agent and water or an alcohol/water mixture.
- the preparation is useful in the removal of abnormal keratinous material, as is to be observed, for example, in onychomycoses, psoriasis of the nail, or warts.
- abnormal keratinous material histological hyperparakeratosis is discernibleas an abnormally changed layer structure of the skin or of the nail and may be treated with the presently disclosed preparation.
- brittle nails can be rehydrated, thus regenerating, for example, the physiological barrier function of the nails.
- Urea has been used in dermatological practice for decades in the form of creams and lotions. Urea changes the structure and the properties of the keratin in the horny layer of the nails. It generally has a hygroscopic action in the horny layer (depending on the carrier), and an antiproliferative action on the epidermis. Urea cleaves disulfide bonds and hydrogen bonds. Through this action, the dead keratinized material is loosened and can then be mechanically detached.
- salicylic acid preparations are customarily used in the form of semisolid preparations such as salicyl petroleum jelly (approximately 20%-60%) or plasters (Guttaplast®).
- semisolid preparations such as salicyl petroleum jelly (approximately 20%-60%) or plasters (Guttaplast®).
- the invention provides a preparation comprising a hydrophilic film-forming agent, urea, water and/or an alcohol/water mixture, which overcomes the disadvantages mentioned for the prior art compounds.
- the preparation according to the invention is an aqueous or aqueous-alcoholic solution, in which the hydrophilic film-forming agent and urea are dissolved or optionally suspended.
- a solution is advantageous.
- the preparation After application to the abnormal keratinous material such as warts or fingernails, the preparation rapidly forms an adherent film which is resistant to wiping and rubbing off.
- the urea penetrates into the abnormal keratin and assists its detachment. Additional covering with plasters, application of a special protective film for the areas of skin surrounding the target site, and daily bathing are not necessary.
- the preparation according to the invention also prevents undesirable precipitation reactions of the urea that occur locally on the keratinous material being treated. Such precipitation leads to unsightly changes or to possible impairment of the local bioavailability of the urea.
- the preparation according to the invention makes possible a uniform distribution of the urea on the keratinous material as a result of its composition and its pharmaceutical properties.
- the present invention provides markedly improved drug targeting by permitting focused application to the target organ or target site with decreased risk for exposure to the adjacent tissue, and an improved user-friendliness (handling) in the application of the preparation.
- the preparation according to the invention therefore provides a formulation comprising
- the preparation can contain further volatile and nonvolatile constituents as long as the amount of urea, based on the nonvolatile constituents of the preparations, is within the specified range.
- the amounts of urea are in each case based on the nonvolatile constituents of the preparation according to the invention and can be from 41 percent by weight to 69 percent by weight, from 45 percent by weight to 65 percent by weight, from 46 percent by weight to 63 percent by weight, or from 55 percent by weight to 63 percent by weight.
- Possible hydrophilic film-forming agents include, for example, acrylic/methacrylic acid ester copolymers, polyvinylpyrrolidones, polyvinyl alcohols, vinyl acetate/vinylpyrrolidone copolymers, vinyl acetate/crotonic acid copolymers, methyl vinyl ether/maleic acid copolymers, polyesters, polyester amides, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and a mixture of two or more of the film-forming agents mentioned.
- the hydrophilic film-forming agent is a polyvinylpyrrolidone.
- the hydrophilic film-forming agents are employed in amounts from 30 percent by weight to 60 percent by weight, relative to the nonvolatile constituents of the preparation.
- the amount of the hydrophilic film-forming agents needed will typically depend on the amount of urea in the preparation.
- suitable alcohols include, for example, (C 1 -C 6 )-alcohols such as methanol, ethanol, propanol, isopropanol (2-propanol), butanol, pentanol hexanol or mixtures thereof.
- ethanol, n-propanol or 2-propanol are employed.
- the ratio of alcohol to water typically ranges from 9:1 to 1:9; In one embodiment, the mixture comprises 2 parts of alcohols to 3 parts of water.
- Suitable additional excipients include plasticizers, such as glycerol triacetate or 1,2-propylene glycol, and agents for adjusting the pH of the preparations, such as lactic acid or citric acid.
- the preparation comprises lactic acid in an amount from 0.5 percent by weight to 5 percent by weight, based on the weight of the entire preparation.
- the preparations according to the invention can furthermore contain additives that are customary in cosmetics, such as plasticizers based on phthalate, glyceryl triacetate or camphor, colorants or color pigments, pearl luster agents, sulfonamide resins, sedimentation-delaying agents, silicates, odoriferous substances, wetting agents such as sodium dioctylsulfosuccinate, lanolin derivatives, sunscreen agents such as 2-hydroxy-4-methoxybenzophenone or antibacterially active substances.
- Colored or pigmented nail varnishes for example, have the advantage that the preparation according to the invention can be tailored to the perception of beauty of the patient and the nail changes existing in the meantime are not immediately visible to third parties.
- the preparation according to the invention is typically prepared by introducing urea and a hydrophilic film-forming agent into water or a water/alcohol mixture and subsequently mixing.
- aqueous-alcoholic solutions are prepared in which the urea is present in dissolved form in an amount from 15 percent by weight to 35 percent by weight, based on the weight of the entire solution.
- the amount of hydrophilic film-forming agent employed is from approximately 15 percent by weight to approximately 35 percent by weight, in each case based on the weight of the entire solution.
- the amount of the hydrophilic film-forming agent employed generally depends on the amount of urea present in the preparation.
- the amount of water or aqueous-alcoholic mixture is from 30 percent by weight to 60 percent by weight, or from 35 percent by weight to 55 percent by weight, in each case based on the weight of the entire solution.
- the preparation according to the invention is typically applied as a solution to the keratinous materials to be treated. It dries rapidly, forming an adherent film which is resistant to wiping and rubbing off.
- the solution can be applied, for example, with a brush.
- the invention further relates to use of the preparation according to the invention for the detachment of abnormal keratinous material.
- abnormal keratinous material is understood as meaning keratinous material in humans and animals such as warts, calluses, hard skin, or toenails and fingernails that have been changed by fungal attack or psoriatic disease. With respect to the abnormal keratinous material, histological hyperparakeratosis is discernibleas an abnormally modified layer structure of the skin or the nail.
- the invention also relates to the use of a preparation comprising
- the amounts of urea are in each case based on the nonvolatile constituents of the use according to the invention and can be from 35 to 85 percent by weight, from 39 percent by weight to 83 percent by weight, from 46 percent by weight to 63 percent by weight, or from 55 percent by weight to 63 percent by weight.
- the hydrophilic film-forming agents are typically employed in amounts from 10 percent by weight to 70 percent by weight, based on the nonvolatile constituents.
- the amount of the hydrophilic film-forming agents employed depends on the amount of urea. For example, mixtures of approximately 25 percent by weight to 35 percent by weight of urea with 15 percent by weight to 20 percent by weight of hydrophilic film-forming agent may be employed, where the weight percentages are relative to the nonvolatile constituents. Such preparations will generally have a shorter drying time than formulations having a higher or lower content of hydrophilic film-forming agent.
- suitable alcohols, film-forming agents, and additional excipients and nonvolatile constituents are as described above for the pharmaceutical preparation
- suitable alcohols, film-forming agents, and additional excipients and nonvolatile constituents are as described above for the pharmaceutical preparation
- amounts of water and/or alcohol, film-forming agents, and additional excipients and non-volatile constituents are also as described above.
- the invention also relates to the use of an aqueous solution comprising urea in an amount from 15 percent to 35 percent, or from 25 percent to 33 percent, based on the weight of the entire solution; and a hydrophilic film-forming agent in an amount from approximately 15 percent to approximately 35 percent, or from 17 percent to 25 percent, in each case based on the weight of the entire solution, for the production of a pharmaceutical for the treatment of abnormal keratinous material.
- the abnormal keratinous material is detached by applying the preparation, allowing a suitable amount of time for the action of the dried preparation on the keratinous material being treated, and subsequent mechanical removal of the abnormal keratinous material.
- the invention further relates to the use of the preparation according to the invention for the hydration of brittle toenails or fingernails.
- a preparation according to the invention has the following composition:
- a preparation according to the invention has the following composition:
- a preparation according to the invention has the following composition:
- a preparation according to the invention has the following composition:
- a preparation according to the invention has the following composition:
- a preparation according to the invention has the following composition:
- Example 3 The toenails of two affected patients were treated with the preparation as in Example 3.
- the preparation of Example 3 was applied once daily to the affected nails with a brush before going to bed.
- the urea-containing film which formed after the application to the nails was wipe-resistant and waterproof. Special protection of the skin areas surrounding the nails and the application of plaster dressings were therefore not necessary. Because of the high water content of the preparations, the affected toenails were not additionally bathed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to a preparation comprising urea, a hydrophilic film-forming agent and water or an alcohol/water mixture. The preparation is useful in the removal of abnormal keratinous material, as is to be observed, for example, in onychomycoses, psoriasis of the nail, or warts. With respect to the abnormal keratinous material, histological hyperparakeratosis is discernibleas an abnormally changed layer structure of the skin or of the nail and may be treated with the presently disclosed preparation. Moreover, by means of this invention brittle nails can be rehydrated, thus regenerating, for example, the physiological barrier function of the nails.
- Urea has been used in dermatological practice for decades in the form of creams and lotions. Urea changes the structure and the properties of the keratin in the horny layer of the nails. It generally has a hygroscopic action in the horny layer (depending on the carrier), and an antiproliferative action on the epidermis. Urea cleaves disulfide bonds and hydrogen bonds. Through this action, the dead keratinized material is loosened and can then be mechanically detached.
- For the detachment or dissolution of changed nails, in particular those that are fungally infested,a cream containing 20% urea (Onychomal®), and an ointment containing 40% urea and the antimycotic Bifonazol® (1%), along have been marketed in a joint pack together with waterproof plasters, an aid for squeezing out, and a nail scraper (Mycospor® nail set). These preparations have been commercially available for over 10 years (Bang D S, Lee Y D, Whang K K, Lee S N, “Therapeutic trial of ointment base including urea and antifungal agent as the treatment of onychomycosis,”Ann. Dermatol., 3: 32-6 (1991); Hay R J, Roberts D T, Doherty V R, Richardson M D, Midgley G, “The topical treatment of onychomycosis using a new combined urea/imidazole preparation,” Clin. Exper. Dermatol., 13: 164-167, (1988)).
- In addition, a nail varnish comprising a hydrophobic film-forming agent, an antimycotic, and urea, which is employed for the treatment of onychomycoses has been described (U.S. Pat. No. 5,346,692).
- Disadvantages in the use of these known preparations include frequent maceration and inflammatory changes in the surrounding skin. Moreover, these semisolid preparations necessitate a dressing on the affected sites in order to prevent wiping off and protection of the surrounding tissue, e.g., by covering with zinc paste. Decisive success was denied to the known treatment methods, since such treatments—for example those requiring plasters on the toes and fingers that are bothersome and appear unsightly and must be applied daily—are frequently not completed by the patients for cosmetic reasons and for reasons of time. The time needed for these customary processes is comparatively high, and the acceptance is limited or the compliance is rapidly exhausted, if, for example, more than 3 to 5 nails have to be treated.
- For the detachment of indurated areas of skin such as in the case of warts, salicylic acid preparations are customarily used in the form of semisolid preparations such as salicyl petroleum jelly (approximately 20%-60%) or plasters (Guttaplast®). Here too, the disadvantages of the semisolid preparations apply analogously.
- The invention provides a preparation comprising a hydrophilic film-forming agent, urea, water and/or an alcohol/water mixture, which overcomes the disadvantages mentioned for the prior art compounds.
- The preparation according to the invention is an aqueous or aqueous-alcoholic solution, in which the hydrophilic film-forming agent and urea are dissolved or optionally suspended. A solution is advantageous. After application to the abnormal keratinous material such as warts or fingernails, the preparation rapidly forms an adherent film which is resistant to wiping and rubbing off. The urea penetrates into the abnormal keratin and assists its detachment. Additional covering with plasters, application of a special protective film for the areas of skin surrounding the target site, and daily bathing are not necessary. The preparation according to the invention also prevents undesirable precipitation reactions of the urea that occur locally on the keratinous material being treated. Such precipitation leads to unsightly changes or to possible impairment of the local bioavailability of the urea. The preparation according to the invention makes possible a uniform distribution of the urea on the keratinous material as a result of its composition and its pharmaceutical properties.
- Unlike the products known in the prior art, the invention therefore offers several advantages. For instance, the present invention provides markedly improved drug targeting by permitting focused application to the target organ or target site with decreased risk for exposure to the adjacent tissue, and an improved user-friendliness (handling) in the application of the preparation.
- The preparation according to the invention therefore provides a formulation comprising
- a) one or more nonvolatile constituents,
- b) urea in an amount from 40 to 70 percent by weight, relative to the nonvolatile constituents of the preparations,
- c) a hydrophilic film-forming agent and
- d) water or an alcohol-water mixture.
- The preparation can contain further volatile and nonvolatile constituents as long as the amount of urea, based on the nonvolatile constituents of the preparations, is within the specified range.
- The amounts of urea are in each case based on the nonvolatile constituents of the preparation according to the invention and can be from 41 percent by weight to 69 percent by weight, from 45 percent by weight to 65 percent by weight, from 46 percent by weight to 63 percent by weight, or from 55 percent by weight to 63 percent by weight.
- Possible hydrophilic film-forming agents include, for example, acrylic/methacrylic acid ester copolymers, polyvinylpyrrolidones, polyvinyl alcohols, vinyl acetate/vinylpyrrolidone copolymers, vinyl acetate/crotonic acid copolymers, methyl vinyl ether/maleic acid copolymers, polyesters, polyester amides, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and a mixture of two or more of the film-forming agents mentioned. In one embodiment, the hydrophilic film-forming agent is a polyvinylpyrrolidone.
- The hydrophilic film-forming agents are employed in amounts from 30 percent by weight to 60 percent by weight, relative to the nonvolatile constituents of the preparation. The amount of the hydrophilic film-forming agents needed will typically depend on the amount of urea in the preparation.
- In the aqueous-alcoholic solutions, suitable alcohols include, for example, (C1-C6)-alcohols such as methanol, ethanol, propanol, isopropanol (2-propanol), butanol, pentanol hexanol or mixtures thereof. In one embodiment, ethanol, n-propanol or 2-propanol are employed. In the aqueous-alcoholic solutions, the ratio of alcohol to water typically ranges from 9:1 to 1:9; In one embodiment, the mixture comprises 2 parts of alcohols to 3 parts of water.
- Suitable additional excipients include plasticizers, such as glycerol triacetate or 1,2-propylene glycol, and agents for adjusting the pH of the preparations, such as lactic acid or citric acid. In one embodiment, the preparation comprises lactic acid in an amount from 0.5 percent by weight to 5 percent by weight, based on the weight of the entire preparation.
- The preparations according to the invention can furthermore contain additives that are customary in cosmetics, such as plasticizers based on phthalate, glyceryl triacetate or camphor, colorants or color pigments, pearl luster agents, sulfonamide resins, sedimentation-delaying agents, silicates, odoriferous substances, wetting agents such as sodium dioctylsulfosuccinate, lanolin derivatives, sunscreen agents such as 2-hydroxy-4-methoxybenzophenone or antibacterially active substances. Colored or pigmented nail varnishes, for example, have the advantage that the preparation according to the invention can be tailored to the perception of beauty of the patient and the nail changes existing in the meantime are not immediately visible to third parties.
- The preparation according to the invention is typically prepared by introducing urea and a hydrophilic film-forming agent into water or a water/alcohol mixture and subsequently mixing. In one embodiment, aqueous-alcoholic solutions are prepared in which the urea is present in dissolved form in an amount from 15 percent by weight to 35 percent by weight, based on the weight of the entire solution. The amount of hydrophilic film-forming agent employed is from approximately 15 percent by weight to approximately 35 percent by weight, in each case based on the weight of the entire solution. The amount of the hydrophilic film-forming agent employed generally depends on the amount of urea present in the preparation. The amount of water or aqueous-alcoholic mixture is from 30 percent by weight to 60 percent by weight, or from 35 percent by weight to 55 percent by weight, in each case based on the weight of the entire solution.
- The preparation according to the invention is typically applied as a solution to the keratinous materials to be treated. It dries rapidly, forming an adherent film which is resistant to wiping and rubbing off. The solution can be applied, for example, with a brush.
- The invention further relates to use of the preparation according to the invention for the detachment of abnormal keratinous material.
- The term “abnormal keratinous material ” is understood as meaning keratinous material in humans and animals such as warts, calluses, hard skin, or toenails and fingernails that have been changed by fungal attack or psoriatic disease. With respect to the abnormal keratinous material, histological hyperparakeratosis is discernibleas an abnormally modified layer structure of the skin or the nail.
- The invention also relates to the use of a preparation comprising
- a) one or more nonvolatile constituents
- b) urea in an amount from 30 percent by weight to 90 percent by weight, relative to the nonvolatile constituents of the preparation,
- c) a hydrophilic film-forming agent and
- d) water or an alcohol-water mixture
- for the production of a pharmaceutical for the treatment and detachment of abnormal keratinous material.
- The amounts of urea are in each case based on the nonvolatile constituents of the use according to the invention and can be from 35 to 85 percent by weight, from 39 percent by weight to 83 percent by weight, from 46 percent by weight to 63 percent by weight, or from 55 percent by weight to 63 percent by weight.
- The hydrophilic film-forming agents are typically employed in amounts from 10 percent by weight to 70 percent by weight, based on the nonvolatile constituents. The amount of the hydrophilic film-forming agents employed depends on the amount of urea. For example, mixtures of approximately 25 percent by weight to 35 percent by weight of urea with 15 percent by weight to 20 percent by weight of hydrophilic film-forming agent may be employed, where the weight percentages are relative to the nonvolatile constituents. Such preparations will generally have a shorter drying time than formulations having a higher or lower content of hydrophilic film-forming agent.
- In the uses according to the invention, suitable alcohols, film-forming agents, and additional excipients and nonvolatile constituents are as described above for the the pharmaceutical preparation The amounts of water and/or alcohol, film-forming agents, and additional excipients and non-volatile constituents are also as described above.
- The invention also relates to the use of an aqueous solution comprising urea in an amount from 15 percent to 35 percent, or from 25 percent to 33 percent, based on the weight of the entire solution; and a hydrophilic film-forming agent in an amount from approximately 15 percent to approximately 35 percent, or from 17 percent to 25 percent, in each case based on the weight of the entire solution, for the production of a pharmaceutical for the treatment of abnormal keratinous material.
- The abnormal keratinous material is detached by applying the preparation, allowing a suitable amount of time for the action of the dried preparation on the keratinous material being treated, and subsequent mechanical removal of the abnormal keratinous material.
- The invention further relates to the use of the preparation according to the invention for the hydration of brittle toenails or fingernails.
- The present invention is explained in greater detail by means of the following examples, but not restricted to these. If not noted otherwise, the quantitative data are based on the weight.
- A preparation according to the invention has the following composition:
- Urea 30%
- Polyvinylpyrrolidone (molecular weight approximately 11 500) 20%
- Demineralized water 50%
- A preparation according to the invention has the following composition:
- Urea 30%
- Polyvinylpyrrolidone (molecular weight approximately 11 500) 20%
- Ethanol 20%
- Demineralized water 30%
- A preparation according to the invention has the following composition:
- Urea 30%
- Polyvinylpyrrolidone (molecular weight approximately 11 500) 20%
- Propan-2-ol 20%
- Lactic acid 1%
- Demineralized water 29%
- A preparation according to the invention has the following composition:
- Urea 30%
- Polyvinylpyrrolidone (molecular weight approximately 11 500) 20%
- Lactic acid 1%
- Demineralized water 49%
- A preparation according to the invention has the following composition:
- Urea 30%
- Polyvinylpyrrolidone (molecular weight approximately 15 000) 20%
- Propan-2-ol 20%
- Demineralized water 30%
- A preparation according to the invention has the following composition:
- Urea 30%
- Polyvinylpyrrolidone (molecular weight approximately 11 500) 20%
- Cremophor EL 1%
- Lactic acid 1%
- Demineralized water 48%
- Activity testing
- The toenails of two affected patients were treated with the preparation as in Example 3. The preparation of Example 3 was applied once daily to the affected nails with a brush before going to bed. The urea-containing film which formed after the application to the nails was wipe-resistant and waterproof. Special protection of the skin areas surrounding the nails and the application of plaster dressings were therefore not necessary. Because of the high water content of the preparations, the affected toenails were not additionally bathed.
- After treatment for approximately 6 days, one of the patients removed the affected areas of the nail and the subungual tissue debris easily with a scraper. The severe nail brittleness had disappeared and the severe hyperkeratosis had improved to a medium degree of severity. After treatment for approximately 6 weeks, the second patient showed that his severe nail brittleness had disappeared and the severe hyperkeratosis was no longer present.
- Both patients showed a good treatment result. The tolerability of the preparation according to the invention was very good. Both patients were very satisfied with the handleability in the application of the preparation.
Claims (30)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/757,433 US7476396B2 (en) | 2001-05-30 | 2004-01-15 | Composition for removing abnormal keratinous material |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10126501.8-41 | 2001-05-30 | ||
DE10126501A DE10126501A1 (en) | 2001-05-30 | 2001-05-30 | Composition used for detaching abnormal keratin material e.g. warts or fungally damage nails, comprises mixture of urea, film former and water or aqueous alcohol |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/757,433 Continuation US7476396B2 (en) | 2001-05-30 | 2004-01-15 | Composition for removing abnormal keratinous material |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020197291A1 true US20020197291A1 (en) | 2002-12-26 |
Family
ID=7686754
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/156,070 Abandoned US20020197291A1 (en) | 2001-05-30 | 2002-05-29 | Composition for removing abnormal keratinous material |
US10/757,433 Expired - Fee Related US7476396B2 (en) | 2001-05-30 | 2004-01-15 | Composition for removing abnormal keratinous material |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/757,433 Expired - Fee Related US7476396B2 (en) | 2001-05-30 | 2004-01-15 | Composition for removing abnormal keratinous material |
Country Status (11)
Country | Link |
---|---|
US (2) | US20020197291A1 (en) |
EP (1) | EP1395231B1 (en) |
JP (1) | JP4359140B2 (en) |
AT (1) | ATE296607T1 (en) |
CA (1) | CA2448829C (en) |
DE (2) | DE10126501A1 (en) |
DK (1) | DK1395231T3 (en) |
ES (1) | ES2242027T3 (en) |
MX (1) | MXPA03009984A (en) |
PT (1) | PT1395231E (en) |
WO (1) | WO2002098380A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030012749A1 (en) * | 2000-01-03 | 2003-01-16 | Karl Kraemer | Preparations for the non-traumatic excision of a nail |
US20040146555A1 (en) * | 2001-05-30 | 2004-07-29 | Aventis Pharma Deutschland Gmbh | Composition for removing abnormal keratinous material |
US20070166249A1 (en) * | 2003-08-25 | 2007-07-19 | Hans Meyer | Pharmaceutical and cosmetic formulations for treating fingernails |
US20090104073A1 (en) * | 2007-10-17 | 2009-04-23 | Nancy-Hope Elizabeth Kaiser | Prion deactivating composition and methods of using same |
US20090191138A1 (en) * | 2008-01-30 | 2009-07-30 | Mediquest Therapeutics, Inc. | Novel topical formulations for improving the appearance of nails |
NL1035426C2 (en) * | 2008-05-15 | 2009-11-17 | Atp Marketing & Promotion Ag | Pharmaceutical compositions for the treatment of warts. |
US20110200544A1 (en) * | 2008-10-21 | 2011-08-18 | Pierre Fabre Dermo-Cosmetique | Urea-based film-forming solution for treating nail psoriasis |
WO2012110430A1 (en) * | 2011-02-10 | 2012-08-23 | Moberg Derma Ab | Novel composition for topical use on a nail |
US9681733B2 (en) | 2011-08-31 | 2017-06-20 | Avon Products, Inc. | Cosmetic liquid extractor comprising nonionic polymers |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004024526D1 (en) * | 2003-04-24 | 2010-01-21 | Oreal | COSMETIC PEELING PROCESS USING UREA |
DE102006049586A1 (en) * | 2006-10-22 | 2008-04-24 | Rudy Susilo | Nail varnish remover comprises urea; fatty acids; allantoin, dexpanthenol, coenzyme Q10 and/or hyaluronic acid; and solvent |
KR101055963B1 (en) * | 2008-12-01 | 2011-08-11 | (주)더페이스샵 | Cosmetic composition for promoting exfoliation |
US9770609B2 (en) | 2015-04-01 | 2017-09-26 | Neat Feat Products Limited | Urea based skin treatment |
AU2015201680B2 (en) * | 2015-04-01 | 2016-12-22 | Neat Feat Products Limited | Urea based skin treatment |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4402935A (en) * | 1981-04-16 | 1983-09-06 | Del Laboratories, Inc. | Moisturizing nail polish composition |
US4721724A (en) * | 1985-06-05 | 1988-01-26 | Bayer Aktiengesellschaft | Formulations containing azole derivatives, and their use for atraumatic nail removal |
US4957730A (en) * | 1985-12-19 | 1990-09-18 | Hoechst Aktiengesellschaft | Antimycotic nail varnish |
US5098421A (en) * | 1989-10-16 | 1992-03-24 | Zook Gerald P | Viscoelastic gel foot padding and medicating device |
US5264206A (en) * | 1987-06-16 | 1993-11-23 | Hoechst Aktiengesellschaft | Nail lacquer with antimycotic activity, and a process for the preparation thereof |
US5346692A (en) * | 1992-04-10 | 1994-09-13 | Roehm Pharma Gmbh | Nail lacquer for the treatment of onychomycosis |
US5460620A (en) * | 1992-07-31 | 1995-10-24 | Creative Products Resource, Inc. | Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent |
US5753256A (en) * | 1993-11-06 | 1998-05-19 | Labtec Gesellschaft Fur Biotechnologische Forschung Und Entwicklung Mbh | Plaster for the treatment of nail mycoses |
US5834513A (en) * | 1996-04-25 | 1998-11-10 | Avon Products, Inc. | Oxa diacids and related compounds for treating skin conditions |
US5874074A (en) * | 1992-12-16 | 1999-02-23 | Creative Products Resource Associates Inc. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
US5919470A (en) * | 1998-04-02 | 1999-07-06 | Bradley Pharmaceuticals, Inc. | Dermatological composition |
US5993790A (en) * | 1997-08-04 | 1999-11-30 | Pedinol Pharmacal Inc. | Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections |
US6281239B1 (en) * | 2000-04-12 | 2001-08-28 | Bradley Pharmeaceuticals, Inc. | Method of treating onychomycosis |
US6429231B1 (en) * | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
US6495602B1 (en) * | 2001-12-13 | 2002-12-17 | Bradley Pharmaceuticals, Inc. | Topical pharmaceutical base with anti-pruritic and/or anti-inflammatory drugs |
US6573301B1 (en) * | 2002-04-23 | 2003-06-03 | Bradley Pharmaceuticals, Inc. | Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use |
US7014913B2 (en) * | 2001-09-27 | 2006-03-21 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3687458T2 (en) | 1985-11-04 | 1993-07-29 | Owen Galderma Lab Inc | FILM-FORMING MEDICINAL PRODUCTS FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS ON NAILS |
FR2613227B1 (en) * | 1987-04-01 | 1990-12-28 | Oreal | PHARMACEUTICAL COMPOSITIONS BASED ON MICONAZOLE NITRATE OR ECONAZOLE NITRATE IN THE TREATMENT OF NAIL FUNGAL INFECTIONS |
US5639740A (en) * | 1995-03-10 | 1997-06-17 | Crandall; Wilson Trafton | Topical moisturizing composition and method |
DE10061801A1 (en) * | 2000-01-03 | 2001-07-12 | Karl Kraemer | New compositions containing hydrophilic film former, water and urea useful for non-traumatic removal of fungally infected areas in finger- and toenails |
DE10126501A1 (en) * | 2001-05-30 | 2002-12-12 | Aventis Pharma Gmbh | Composition used for detaching abnormal keratin material e.g. warts or fungally damage nails, comprises mixture of urea, film former and water or aqueous alcohol |
US6673842B2 (en) * | 2002-03-20 | 2004-01-06 | Bradley Pharmaceuticals, Inc. | Method of treating onychomycosis |
US6743417B2 (en) * | 2002-04-22 | 2004-06-01 | Bradley Pharmaceuticals, Inc. | Method of treating onychomycosis with urea and an antioxidant |
-
2001
- 2001-05-30 DE DE10126501A patent/DE10126501A1/en not_active Withdrawn
-
2002
- 2002-05-17 PT PT02732724T patent/PT1395231E/en unknown
- 2002-05-17 MX MXPA03009984A patent/MXPA03009984A/en active IP Right Grant
- 2002-05-17 AT AT02732724T patent/ATE296607T1/en active
- 2002-05-17 ES ES02732724T patent/ES2242027T3/en not_active Expired - Lifetime
- 2002-05-17 DK DK02732724T patent/DK1395231T3/en active
- 2002-05-17 CA CA2448829A patent/CA2448829C/en not_active Expired - Fee Related
- 2002-05-17 EP EP02732724A patent/EP1395231B1/en not_active Expired - Lifetime
- 2002-05-17 WO PCT/EP2002/005469 patent/WO2002098380A1/en active IP Right Grant
- 2002-05-17 JP JP2003501422A patent/JP4359140B2/en not_active Expired - Fee Related
- 2002-05-17 DE DE50203283T patent/DE50203283D1/en not_active Expired - Lifetime
- 2002-05-29 US US10/156,070 patent/US20020197291A1/en not_active Abandoned
-
2004
- 2004-01-15 US US10/757,433 patent/US7476396B2/en not_active Expired - Fee Related
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4402935A (en) * | 1981-04-16 | 1983-09-06 | Del Laboratories, Inc. | Moisturizing nail polish composition |
US4721724A (en) * | 1985-06-05 | 1988-01-26 | Bayer Aktiengesellschaft | Formulations containing azole derivatives, and their use for atraumatic nail removal |
US4957730A (en) * | 1985-12-19 | 1990-09-18 | Hoechst Aktiengesellschaft | Antimycotic nail varnish |
US5264206A (en) * | 1987-06-16 | 1993-11-23 | Hoechst Aktiengesellschaft | Nail lacquer with antimycotic activity, and a process for the preparation thereof |
US5098421A (en) * | 1989-10-16 | 1992-03-24 | Zook Gerald P | Viscoelastic gel foot padding and medicating device |
US5346692A (en) * | 1992-04-10 | 1994-09-13 | Roehm Pharma Gmbh | Nail lacquer for the treatment of onychomycosis |
US5460620A (en) * | 1992-07-31 | 1995-10-24 | Creative Products Resource, Inc. | Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent |
US5874074A (en) * | 1992-12-16 | 1999-02-23 | Creative Products Resource Associates Inc. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
US5753256A (en) * | 1993-11-06 | 1998-05-19 | Labtec Gesellschaft Fur Biotechnologische Forschung Und Entwicklung Mbh | Plaster for the treatment of nail mycoses |
US5834513A (en) * | 1996-04-25 | 1998-11-10 | Avon Products, Inc. | Oxa diacids and related compounds for treating skin conditions |
US5993790A (en) * | 1997-08-04 | 1999-11-30 | Pedinol Pharmacal Inc. | Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections |
US5919470A (en) * | 1998-04-02 | 1999-07-06 | Bradley Pharmaceuticals, Inc. | Dermatological composition |
US6281239B1 (en) * | 2000-04-12 | 2001-08-28 | Bradley Pharmeaceuticals, Inc. | Method of treating onychomycosis |
US6380236B2 (en) * | 2000-04-12 | 2002-04-30 | Bradley Pharmaceuticals, Inc. | Method of treating onychomycosis |
US6429231B1 (en) * | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
US7014913B2 (en) * | 2001-09-27 | 2006-03-21 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US6495602B1 (en) * | 2001-12-13 | 2002-12-17 | Bradley Pharmaceuticals, Inc. | Topical pharmaceutical base with anti-pruritic and/or anti-inflammatory drugs |
US6573301B1 (en) * | 2002-04-23 | 2003-06-03 | Bradley Pharmaceuticals, Inc. | Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030012749A1 (en) * | 2000-01-03 | 2003-01-16 | Karl Kraemer | Preparations for the non-traumatic excision of a nail |
US7476396B2 (en) | 2001-05-30 | 2009-01-13 | Sanofi-Aventis Deutschland Gmbh | Composition for removing abnormal keratinous material |
US20040146555A1 (en) * | 2001-05-30 | 2004-07-29 | Aventis Pharma Deutschland Gmbh | Composition for removing abnormal keratinous material |
AU2004266053B2 (en) * | 2003-08-25 | 2011-06-09 | Bioequal Ag | Pharmaceutical and cosmetic formulations for treating fingernails |
US20070166249A1 (en) * | 2003-08-25 | 2007-07-19 | Hans Meyer | Pharmaceutical and cosmetic formulations for treating fingernails |
US20090104073A1 (en) * | 2007-10-17 | 2009-04-23 | Nancy-Hope Elizabeth Kaiser | Prion deactivating composition and methods of using same |
US8293174B2 (en) * | 2007-10-17 | 2012-10-23 | American Sterilizer Company | Prion deactivating composition and methods of using same |
US20090191138A1 (en) * | 2008-01-30 | 2009-07-30 | Mediquest Therapeutics, Inc. | Novel topical formulations for improving the appearance of nails |
NL1035426C2 (en) * | 2008-05-15 | 2009-11-17 | Atp Marketing & Promotion Ag | Pharmaceutical compositions for the treatment of warts. |
WO2009138487A1 (en) * | 2008-05-15 | 2009-11-19 | Atp Marketing & Promotion Ag | Pharmaceutical compositions for the treatment of warts |
US20110117222A1 (en) * | 2008-05-15 | 2011-05-19 | Atp Marketing & Promotion Ag | Pharmaceutical Compositions for the Treatment of Warts |
EA018216B1 (en) * | 2008-05-15 | 2013-06-28 | Атп Маркетинг Энд Промоушн Аг | Pharmaceutical compositions for the treatment of warts |
US20110200544A1 (en) * | 2008-10-21 | 2011-08-18 | Pierre Fabre Dermo-Cosmetique | Urea-based film-forming solution for treating nail psoriasis |
WO2012110430A1 (en) * | 2011-02-10 | 2012-08-23 | Moberg Derma Ab | Novel composition for topical use on a nail |
US9681733B2 (en) | 2011-08-31 | 2017-06-20 | Avon Products, Inc. | Cosmetic liquid extractor comprising nonionic polymers |
Also Published As
Publication number | Publication date |
---|---|
CA2448829A1 (en) | 2002-12-12 |
DE10126501A1 (en) | 2002-12-12 |
US20040146555A1 (en) | 2004-07-29 |
DK1395231T3 (en) | 2005-09-12 |
ATE296607T1 (en) | 2005-06-15 |
PT1395231E (en) | 2005-08-31 |
WO2002098380A1 (en) | 2002-12-12 |
DE50203283D1 (en) | 2005-07-07 |
JP2004532268A (en) | 2004-10-21 |
EP1395231B1 (en) | 2005-06-01 |
EP1395231A1 (en) | 2004-03-10 |
ES2242027T3 (en) | 2005-11-01 |
JP4359140B2 (en) | 2009-11-04 |
CA2448829C (en) | 2010-04-20 |
MXPA03009984A (en) | 2004-02-12 |
US7476396B2 (en) | 2009-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5993790A (en) | Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections | |
US5487776A (en) | Anti-fungal nail lacquer and method therefor | |
US7476396B2 (en) | Composition for removing abnormal keratinous material | |
KR101453218B1 (en) | Cosmetics compositions for conditioning | |
JP5780623B2 (en) | Rinsable mask-type cosmetic composition for skin care | |
JPS62155205A (en) | Fungicidal manicure liquid | |
JPH10152433A (en) | Film-forming antifungal agent composition | |
EP0879052B1 (en) | Preparations stimulating nail growth | |
JP2000229834A (en) | Cosmetic | |
KR100667124B1 (en) | Cholesterol Sulfate Compositions for Enhancement of Stratum Corneum Function | |
BG63589B1 (en) | The use of glyceryltriacetate for the treatment of onychomycosis | |
US20030012749A1 (en) | Preparations for the non-traumatic excision of a nail | |
CA2351695A1 (en) | Topical compositions including deodorant compositions | |
JPH0899819A (en) | Anti-fungus pharmaceutical preparation for making-up and dermatology | |
US20060280703A1 (en) | Antimycotic nail varnish | |
JPH0778026B2 (en) | Topical base for skin | |
McMullen | Maleic anhydride applications in personal care | |
KR102084521B1 (en) | Compositions for prevention and improvement of acne | |
HU210426B (en) | Process for producing a preparation for the treatment of fungal infections in the oral cavity of patients with dental prothesis | |
JP2001513747A (en) | Antifungal nail lacquer and its preparation | |
AU707437C (en) | Anti-fugal nail lacquer and method therefor | |
KR20040043596A (en) | Anti-keratin composition comprising cellulose as a effective component | |
KR20150088582A (en) | Cosmetics compositions for hair growth inhibitor | |
Yadav et al. | TRANSUNGUAL DRUG DELIVERY: PAST, PRESENT & FUTURE TRENDS | |
EA044018B1 (en) | COSMETIC COMPOSITION AND METHODS OF ITS APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ULBRICHT, HORST;POOTH, RAINER;SHUSTER, SAMUEL;REEL/FRAME:013232/0623;SIGNING DATES FROM 20020805 TO 20020820 |
|
AS | Assignment |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789 Effective date: 20050901 Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH,GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789 Effective date: 20050901 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |